ACE Inhibitors -
-20% with code BOOKS
Shipping in 12-18 days
30-day return policy
Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun tries [1]. CAPTOPRIL, t ... Full description
You May Also Like
TOP
The Myth of Normal: Trauma, Illness, and Healing in a Toxic Culture
-20% with code BOOKS
In stock
TOP
Maybe You Should Talk to Someone: a therapist, her thearapist, and our lives revealed
-20% with code BOOKS
In stock at our supplier
TOP
On Connection: 'Powerful' MATT HAIG
-20% with code BOOKS
In stock at our supplier
TOP
Harrison's Principles of Internal Medicine (Vol.1 & Vol.2)
Stephen Hauser, Joseph Loscalzo, Steven Holland, Dan Longo, J. Larry Jameson, Dennis Kasper, Carol Langford, Anthony Fauci
-20% with code BOOKS
In stock at our supplier
TOP
The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma
-20% with code BOOKS
In stock at our supplier
TOP
No Bad Parts: Healing Trauma and Restoring Wholeness with the Internal Family Systems Model
-20% with code BOOKS
In stock at our supplier
TOP
The Checklist Manifesto: How to Get Things Right
-20% with code BOOKS
In stock at our supplier
TOP
Attached: Are you Anxious, Avoidant or Secure? How the science of adult attachment can help you find - and keep - love
Amir Levine, Rachel S.F. Heller
-20% with code BOOKS
In stock at our supplier
TOP
Lifespan: Why We Age - and Why We Don't Have To
-20% with code BOOKS
In stock at our supplier
TOP
Aids to the Examination of the Peripheral Nervous System
-20% with code BOOKS
In stock at our supplier
TOP
ROAR: How to Match Your Food and Fitness to Your Unique Female Physiology for Optimum Performance, Great Health, and a Strong, Lean Body for Life
-20% with code BOOKS
In stock at our supplier
TOP
Cellular and Molecular Immunology
Sarah Henrickson, Abul K. Abbas, Andrew H. Lichtman, Shiv Pillai
-20% with code BOOKS
In stock at our supplier
TOP
The Autistic Burnout Workbook: Your Guide to Your Personal Recovery Plan
-20% with code BOOKS
In stock at our supplier
TOP
Physics, Pharmacology and Physiology for Anaesthetists: Key Concepts for the FRCA
Matthew E. Cross, Emma V. E. Plunkett
-20% with code BOOKS
In stock at our supplier
TOP
Oxford Handbook of Clinical Medicine
Peter Hateley, Iain McGurgan, Ian B. Wilkinson, Tim Raine, Dearbhla Kelly, Kate Wiles
-20% with code BOOKS
In stock at our supplier
TOP
Pocket Guide to Teaching for Clinical Instructors
-20% with code BOOKS
In stock at our supplier
TOP
Oxford Handbook of Critical Care
Andrew Webb, Mervyn Singer, Alice Carter
-20% with code BOOKS
In stock at our supplier
TOP
The Wills Eye Manual: Print + eBook with Multimedia: Office and Emergency Room Diagnosis and Treatment of Eye Disease
-20% with code BOOKS
In stock at our supplier
Description
Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun tries [1]. CAPTOPRIL, the prototype of the "PRIL" family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop ment almost failed when serious side-effects were reported in an alarmist fash ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb & Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the "PRIL" family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B , ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar macological actions.
More Information
| Publisher | Birkhäuser Basel |
|---|---|
| Series | Milestones in Drug Therapy |
| Release year | 2012 |
| Cover type | Softcover |
| EAN | 9783034875813 |